PrioClear is incorporated into Octapharma’s manufacturing process for its solvent/detergent treated plasma product, Octaplas, which is currently approved for marketing in US and several European countries.
The order stems from an ongoing supply agreement between both the companies and is expected to increase total shipments to Octapharma in 2013 over 2012.
ProMetic Life Sciences president and chief executive officer Pierre Laurin said that the new purchase order confirms the company’s growth forecast for shipments to Octapharma.
"We anticipate further growth in the coming years as they continue to gain market share in more mature markets and grow their sales in newer markets," Laurin added.
ProMetic is also developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies.
The company has R&D facilities in the UK, the US and Canada, manufacturing facilities in the UK and business development activities in the US, Europe and Asia.